NIH R01 · 2024
Renal Denervation to Treat Polycystic Kidney Disease: Mechanisms and Mediators
Polycystic kidney disease (PKD), both autosomal dominant (AD) and autosomal recessive (AR) forms, remains the leading cause of inheritable kidney disease in adults and children throughout the US as well as worldwide. Though the pathogenesis of renal cyst formation is understood to be driven primarily by a loss-of-function mutation in the polycystin in ADPKD and fibrocystin gene in ARPKD, there remains no cure for these diseases beyond kidney transplantation. Vasopressin (AVP) signaling blockade has been demonstrated to blunt cyst formation, specifically through pharmacological targeting of AVP receptor type 2 (V2R) with Tolvaptan. While V2R antagonism may benefit the patient by delaying…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.